UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Eteplirsen Approval Could Add $500M/Yr. to Sarepta Therapeutics (SRPT) Top Line - Barron's
April 21, 2014 3:46 PM EDTSarepta Therapeutics (Nasdaq: SRPT) is up today following news that it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular... More
FDA Feedback 'Best Case Scenario' for Sarepta Therapeutic (SRPT), Baird Said; PT Lifted
April 21, 2014 3:41 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $35 to $53 calling the FDA feedback the 'best case scenario.'
Skorney said, "The final FDA minutes reflected several positive outcomes: 1) validation of a historically controlled... More
William Blair Upgrades Sarepta Therapeutic (SRPT) to Outperform (Earlier)
April 21, 2014 11:10 AM EDTWilliam Blair upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $63.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $24.40 yesterday.
... MoreJMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
April 21, 2014 11:08 AM EDTJMP Securities upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Market Outperform with a price target of $54.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $24.40 yesterday.
... MoreSarepta Therapeutic (SRPT) Target Ratcheted Higher at Needham & Company
April 21, 2014 10:49 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $36 to $52 after a path to accelerated approval of was reached with the FDA.
"Based on a guidance letter recently... More
Sarepta (SRPT) Plans to Submit NDA for Eteplirsen by End of 2014
April 21, 2014 6:57 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Eteplirsen is Sareptas lead exon-skipping drug candidate in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.
The plan to submit an NDA for eteplirsen by the end of 2014 is based on a guidance letter from... More
